Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer

Woojin Jeong, Sang Bae Kim, Bo Hwa Sohn, Yun Yong Park, Eun Sung Park, Sang Cheol Kim, Sung Soo Kim, Randy L. Johnson, Michael Birrer, David S.L. Bowtell, Gordon Mills, Anil Sood, Ju Seog Lee

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Aim: We aimed to investigate the clinical significance of the activation of Yes-Associated Protein 1 (YAP1), a key downstream effector of Hippo tumor-suppressor pathway, in ovarian cancer. Materials and Methods: A gene expression signature reflecting activation of YAP1 was developed from gene expression data of 267 samples from patients with ovarian cancer. A refined ovarian cancer YAP1 signature was validated in an independent ovarian cancer cohort (n=185). Associations between the YAP1 signature and prognosis were assessed using Kaplan-Meier plots, the log-rank test, and a Cox proportional hazards model. Results: We identified a 612-gene expression signature reflecting YAP1 activation in ovarian cancer. In multivariate analysis, the signature was an independent predictor of overall survival (hazard ratio=1.66; 95% confidence interval=1.1 to 2.53; p=0.01). In subset analysis, the signature identified patients likely to benefit from taxane-based adjuvant chemotherapy. Conclusion: Activation of YAP1 is significantly associated with prognosis and the YAP1 signature can predict response to taxane-based adjuvant chemotherapy in patients with ovarian cancer.

Original languageEnglish (US)
Pages (from-to)811-818
Number of pages8
JournalAnticancer Research
Volume34
Issue number2
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Taxoids
Ovarian Neoplasms
Proteins
Adjuvant Chemotherapy
Transcriptome
Proportional Hazards Models
Multivariate Analysis
Confidence Intervals
Gene Expression
Survival

Keywords

  • DNA microarrays
  • Ovarian cancer
  • Prognosis
  • Taxane
  • YAP1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jeong, W., Kim, S. B., Sohn, B. H., Park, Y. Y., Park, E. S., Kim, S. C., ... Lee, J. S. (2014). Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Research, 34(2), 811-818.

Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. / Jeong, Woojin; Kim, Sang Bae; Sohn, Bo Hwa; Park, Yun Yong; Park, Eun Sung; Kim, Sang Cheol; Kim, Sung Soo; Johnson, Randy L.; Birrer, Michael; Bowtell, David S.L.; Mills, Gordon; Sood, Anil; Lee, Ju Seog.

In: Anticancer Research, Vol. 34, No. 2, 01.01.2014, p. 811-818.

Research output: Contribution to journalArticle

Jeong, W, Kim, SB, Sohn, BH, Park, YY, Park, ES, Kim, SC, Kim, SS, Johnson, RL, Birrer, M, Bowtell, DSL, Mills, G, Sood, A & Lee, JS 2014, 'Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer', Anticancer Research, vol. 34, no. 2, pp. 811-818.
Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC et al. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Research. 2014 Jan 1;34(2):811-818.
Jeong, Woojin ; Kim, Sang Bae ; Sohn, Bo Hwa ; Park, Yun Yong ; Park, Eun Sung ; Kim, Sang Cheol ; Kim, Sung Soo ; Johnson, Randy L. ; Birrer, Michael ; Bowtell, David S.L. ; Mills, Gordon ; Sood, Anil ; Lee, Ju Seog. / Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. In: Anticancer Research. 2014 ; Vol. 34, No. 2. pp. 811-818.
@article{46600c8fdefc4acba6a6da5c5ad043b7,
title = "Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer",
abstract = "Aim: We aimed to investigate the clinical significance of the activation of Yes-Associated Protein 1 (YAP1), a key downstream effector of Hippo tumor-suppressor pathway, in ovarian cancer. Materials and Methods: A gene expression signature reflecting activation of YAP1 was developed from gene expression data of 267 samples from patients with ovarian cancer. A refined ovarian cancer YAP1 signature was validated in an independent ovarian cancer cohort (n=185). Associations between the YAP1 signature and prognosis were assessed using Kaplan-Meier plots, the log-rank test, and a Cox proportional hazards model. Results: We identified a 612-gene expression signature reflecting YAP1 activation in ovarian cancer. In multivariate analysis, the signature was an independent predictor of overall survival (hazard ratio=1.66; 95{\%} confidence interval=1.1 to 2.53; p=0.01). In subset analysis, the signature identified patients likely to benefit from taxane-based adjuvant chemotherapy. Conclusion: Activation of YAP1 is significantly associated with prognosis and the YAP1 signature can predict response to taxane-based adjuvant chemotherapy in patients with ovarian cancer.",
keywords = "DNA microarrays, Ovarian cancer, Prognosis, Taxane, YAP1",
author = "Woojin Jeong and Kim, {Sang Bae} and Sohn, {Bo Hwa} and Park, {Yun Yong} and Park, {Eun Sung} and Kim, {Sang Cheol} and Kim, {Sung Soo} and Johnson, {Randy L.} and Michael Birrer and Bowtell, {David S.L.} and Gordon Mills and Anil Sood and Lee, {Ju Seog}",
year = "2014",
month = "1",
day = "1",
language = "English (US)",
volume = "34",
pages = "811--818",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer

AU - Jeong, Woojin

AU - Kim, Sang Bae

AU - Sohn, Bo Hwa

AU - Park, Yun Yong

AU - Park, Eun Sung

AU - Kim, Sang Cheol

AU - Kim, Sung Soo

AU - Johnson, Randy L.

AU - Birrer, Michael

AU - Bowtell, David S.L.

AU - Mills, Gordon

AU - Sood, Anil

AU - Lee, Ju Seog

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aim: We aimed to investigate the clinical significance of the activation of Yes-Associated Protein 1 (YAP1), a key downstream effector of Hippo tumor-suppressor pathway, in ovarian cancer. Materials and Methods: A gene expression signature reflecting activation of YAP1 was developed from gene expression data of 267 samples from patients with ovarian cancer. A refined ovarian cancer YAP1 signature was validated in an independent ovarian cancer cohort (n=185). Associations between the YAP1 signature and prognosis were assessed using Kaplan-Meier plots, the log-rank test, and a Cox proportional hazards model. Results: We identified a 612-gene expression signature reflecting YAP1 activation in ovarian cancer. In multivariate analysis, the signature was an independent predictor of overall survival (hazard ratio=1.66; 95% confidence interval=1.1 to 2.53; p=0.01). In subset analysis, the signature identified patients likely to benefit from taxane-based adjuvant chemotherapy. Conclusion: Activation of YAP1 is significantly associated with prognosis and the YAP1 signature can predict response to taxane-based adjuvant chemotherapy in patients with ovarian cancer.

AB - Aim: We aimed to investigate the clinical significance of the activation of Yes-Associated Protein 1 (YAP1), a key downstream effector of Hippo tumor-suppressor pathway, in ovarian cancer. Materials and Methods: A gene expression signature reflecting activation of YAP1 was developed from gene expression data of 267 samples from patients with ovarian cancer. A refined ovarian cancer YAP1 signature was validated in an independent ovarian cancer cohort (n=185). Associations between the YAP1 signature and prognosis were assessed using Kaplan-Meier plots, the log-rank test, and a Cox proportional hazards model. Results: We identified a 612-gene expression signature reflecting YAP1 activation in ovarian cancer. In multivariate analysis, the signature was an independent predictor of overall survival (hazard ratio=1.66; 95% confidence interval=1.1 to 2.53; p=0.01). In subset analysis, the signature identified patients likely to benefit from taxane-based adjuvant chemotherapy. Conclusion: Activation of YAP1 is significantly associated with prognosis and the YAP1 signature can predict response to taxane-based adjuvant chemotherapy in patients with ovarian cancer.

KW - DNA microarrays

KW - Ovarian cancer

KW - Prognosis

KW - Taxane

KW - YAP1

UR - http://www.scopus.com/inward/record.url?scp=84897067669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897067669&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 811

EP - 818

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -